Back to Newsroom

Cynapsus Reports Third Quarter 2015 Financial Results and Recent Developments

Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH) (“Cynapsus” or the “Company”), a specialty central nervous system (“CNS”) pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson’s disease (“PD”), today announced financial results for the three and nine months ended September 30, 2015. Unless specified otherwise, all amounts are in Canadian dollars.


Read more here.